Emcure makes Gennova wholly-owned subsidiary for Rs. 2,318.7 Million

1 min read Updated on 22 Jul 2026, 08:22 PM

Reviewed by

Shriram SScanX News Team

AI Summary

Emcure Pharmaceuticals has acquired the remaining 12.05% stake in Gennova Biopharmaceuticals for Rs. 2,318.7 Million, converting it into a wholly-owned subsidiary. The transaction involved 663,865 equity shares and was completed on July 21, 2026. Gennova reported a turnover of Rs. 4,917.42 Million for FY26.

*this image is generated using AI for illustrative purposes only.

Emcure Pharmaceuticals has completed the acquisition of a 12.05% stake in Gennova Biopharmaceuticals Limited for an aggregate consideration of Rs. 2,318.7 Million, making the target entity a wholly-owned subsidiary. The company acquired 663,865 equity shares from individual shareholders, which were duly credited to its demat account on July 21, 2026. This strategic move increases Emcure's shareholding in Gennova from 87.95% to 100%, consolidating control over the biotechnology firm involved in research, development, manufacturing, and marketing of biotechnology-based products.

The acquisition was executed pursuant to Share Transfer Agreements signed on July 13, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transaction was undertaken at arm's length, with the consideration paid in cash. Gennova reported a turnover of Rs. 4,917.42 Million and a Profit After Tax (PAT) of Rs. 54.25 Million for the financial year ended March 31, 2026.

Financial Overview of Gennova Biopharmaceuticals

Gennova Biopharmaceuticals, incorporated on June 19, 2001, operates within the pharmaceuticals industry. The entity has demonstrated consistent revenue growth over the past three financial years.

Financial Year	Turnover (Rs. Million)
FY 2025-26	4,917.42
FY 2024-25	4,299.46
FY 2023-24	4,220.82

Transaction Details

The acquisition was funded entirely through cash consideration. The deal structure involved purchasing the remaining stake held by individual shareholders, thereby eliminating minority interest. No governmental or regulatory approvals were required for the completion of this transaction.

Particulars	Details
Target Entity	Gennova Biopharmaceuticals Limited
Shares Acquired	663,865 Equity Shares
Percentage Acquired	12.05%
Total Consideration	Rs. 2,318.7 Million
Nature of Consideration	Cash
Post-Acquisition Shareholding	100%

The completion of this acquisition aligns with Emcure's strategy to strengthen its presence in the biotechnology sector. Gennova's operations are entirely based in India, and its integration as a wholly-owned subsidiary is expected to streamline decision-making and operational efficiencies.

Historical Stock Returns for Emcure Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.83%	+4.37%	+5.48%	+21.27%	+39.13%	+39.00%

How will Emcure utilize the full control of Gennova to accelerate the R&D and commercialization of new biotechnology-based products?

What specific operational efficiencies and cost synergies does Emcure expect to realize now that Gennova is a wholly-owned subsidiary?

Will Emcure look to integrate Gennova's proprietary mRNA technology platform into its broader pharmaceutical portfolio to diversify its revenue streams?

Read Next Article

Emcure Pharmaceuticals director P.S. Jayakumar ceases to be director

0 min read Updated on 21 Jul 2026, 04:20 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

AI Summary

P.S. Jayakumar ceased to be an Independent Director of Emcure Pharmaceuticals Limited on July 21, 2026, after completing his second term. He also vacated his roles as Chairman of the Audit Committee and Member of the Nomination and Remuneration Committee and Risk Management Committee.

*this image is generated using AI for illustrative purposes only.

P.S. Jayakumar has ceased to be an Independent Director of emcure pharmaceuticals with effect from the close of business hours on July 21, 2026. This development follows the completion of his second consecutive term on the Board, necessitating his departure in accordance with regulatory norms. The change impacts the company's governance structure as he vacated key leadership roles within its board committees.

Consequent to his cessation as a director, Mr. Jayakumar also stepped down from his positions on specific Board Committees effective July 21, 2026. He had served as the Chairman of the Audit Committee and was a Member of both the Nomination and Remuneration Committee and the Risk Management Committee. The Board acknowledged his contributions during his tenure.

The disclosure was made to the exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was formally submitted by Amruta Yangalwar, Company Secretary & Compliance Officer.